Search alternatives:
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), showed decreased (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), showed decreased (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
-
2281
The result of molecular dynamics simulation.
Published 2025“…The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. …”
-
2282
Result of the phenotypic analysis.
Published 2025“…The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. …”
-
2283
Type of Mutations.
Published 2025“…The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. …”
-
2284
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
-
2285
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
-
2286
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
-
2287
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
-
2288
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
-
2289
-
2290
Baseline analysis, nominal factors.
Published 2025“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
-
2291
Minimal dataset for the study.
Published 2025“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
-
2292
Baseline analysis, continuous factors.
Published 2025“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
-
2293
Multivariable analysis between 2006 and 2018.
Published 2025“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
-
2294
<b> </b> Energy efficiency and gas volume comparison.
Published 2025“…CO₂ yield was higher in the control group at lower temperatures, while the integrated system consistently produced more biochar and biogas. …”
-
2295
Model validation of kinetic parameters.
Published 2025“…CO₂ yield was higher in the control group at lower temperatures, while the integrated system consistently produced more biochar and biogas. …”
-
2296
-
2297
-
2298
-
2299
Graphical abstract regarding program development.
Published 2024“…<div><p>The stigma surrounding mental health remains a significant barrier to help-seeking and well-being in youth populations. …”
-
2300
Phases of the intervention program.
Published 2024“…<div><p>The stigma surrounding mental health remains a significant barrier to help-seeking and well-being in youth populations. …”